Clinical Trial

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress

Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s…

5 months ago

DiagnaMed Expands with Drug and Clinical Research AI Platform

Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development…

5 months ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing…

5 months ago

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

Expansion of leadership team to strengthen global clinical expertiseBRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:…

5 months ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

5 months ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company…

5 months ago

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better…

5 months ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Patented personalized medicine approach for patient dosing for autologous cell therapyExpected to meaningfully enhance clinical experience and market opportunity SUNNYVALE,…

5 months ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes…

5 months ago

Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

Strategic equity investment of $15 M to support completion of Pharmazz's pivotal Phase 3 study for Sovateltide to treat patients…

5 months ago